Business
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq® subcutaneous formulation with ENHANZE® reduces
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain \nTecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 minutes for standard intravenous infusion\nSAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug delivery technology, by the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Tecentriq® subcutaneous (SC) is co-formulated with Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenous (IV) infusion. Tecentriq® SC will be available to patients in Great Britain for certain types of lung, bladder, breast, and liver cancer.7\nMultiple oncology studies suggest that most cancer patients prefer to receive their treatments via subcutaneous delivery, instead of intravenous infusion because of reduced discomfort, ease of administration, and shorter duration of treatment.2,4,11 \n\"We are delighted that Roche has received approval of Tecentriq SC in Great Britain. Subcutaneous delivery of Tecentriq provides cancer patients a faster and more flexible treatment option and may alleviate pressure on healthcare system resources,\" said Dr. Helen Torley, president and chief executive officer of Halozyme. \"We look forward to additional regulatory approvals of our partner products utilizing ENHANZE.\"\nTecentriq® SC is the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain and is Roche's fourth subcutaneous cancer therapy using Halozyme's ENHANZE® drug delivery technology.8-10 The approval is based on clinical data from the Phase IB/III IMscin001 study, which showed comparable levels of Tecentriq® in the blood when administered subcutaneously, and a safety and efficacy profile consistent with the IV formulation.12 While the IMscin001 trial was conducted within the hospital setting, the SC formulation may be suitable for out-of-hospital administration by a healthcare professional.\nThe U.S. Food and Drug Administration (FDA) is currently evaluating Tecentriq® SC for regulatory approval.\nAbout Halozyme\nHaloz...